246 related articles for article (PubMed ID: 37198319)
1. Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype.
Aprile M; Cataldi S; Perfetto C; Federico A; Ciccodicola A; Costa V
Br J Cancer; 2023 Aug; 129(2):249-265. PubMed ID: 37198319
[TBL] [Abstract][Full Text] [Related]
2. Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms.
Xu Q; Wang J; Mao Y; Xuan Z; Yang K; Tang X; Zhu X
Neoplasia; 2024 Jun; 52():100996. PubMed ID: 38593698
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
[TBL] [Abstract][Full Text] [Related]
4. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
5. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.
Zerilli M; Zito G; Martorana A; Pitrone M; Cabibi D; Cappello F; Giordano C; Rodolico V
Mod Pathol; 2010 Aug; 23(8):1052-60. PubMed ID: 20473281
[TBL] [Abstract][Full Text] [Related]
6. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
[No Abstract] [Full Text] [Related]
7. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
9. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
10. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
12. Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.
Limberg J; Egan CE; Gray KD; Singh M; Loewenstein Z; Yang Y; Riascos MC; Al Asadi H; Safe P; El Eshaky S; Liang H; Ullmann TM; Wang W; Li W; Zhang T; Xiang J; Stefanova D; Jin MM; Zarnegar R; Fahey TJ; Min IM
Mol Cancer Res; 2023 May; 21(5):397-410. PubMed ID: 36790391
[TBL] [Abstract][Full Text] [Related]
13. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
14. BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
Bonaldi E; Gargiuli C; De Cecco L; Micali A; Rizzetti MG; Greco A; Borrello MG; Minna E
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072194
[No Abstract] [Full Text] [Related]
15. In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.
Ilie MI; Lassalle S; Long-Mira E; Hofman V; Zangari J; Bénaim G; Bozec A; Guevara N; Haudebourg J; Birtwisle-Peyrottes I; Santini J; Brest P; Hofman P
Virchows Arch; 2013 Sep; 463(3):437-44. PubMed ID: 23893334
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.
Zaballos MA; Acuña-Ruiz A; Morante M; Riesco-Eizaguirre G; Crespo P; Santisteban P
Cell Mol Life Sci; 2022 Sep; 79(9):504. PubMed ID: 36056964
[TBL] [Abstract][Full Text] [Related]
18. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
19. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
